.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Teva
Cipla
Daiichi Sankyo
UBS
QuintilesIMS
Dow
Farmers Insurance
Merck
McKinsey

Generated: December 13, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,071,577

« Back to Dashboard

Claims for Patent: 8,071,577

Title:Multi-phase contraceptive preparation based on a natural estrogen
Abstract: The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenone. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenone and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenone, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.
Inventor(s): Endrikat; Jan (Kirkland, CA), Duesterberg; Bernd (Oberkraemer, DE)
Assignee: Bayer Pharma Aktiengesellschaft (Berlin, DE)
Application Number:11/578,771
Patent Claims: 1. A multiphase product for contraception comprising: a first phase of 2 daily dosage units, each comprising 3 mg of estradiol valerate, a second phase of 2 groups of daily dosage units, a first group comprising 5 daily dosage units, each of which comprises 2 mg of estradiol valerate and 2 mg of dienogest, and a second group comprising 17 daily dosage units, each of which comprises 2 mg of estradiol valerate and 3 mg of dienogest; a third phase of 2 two daily dosage units, each comprising 1 mg of estradiol valerate, and a fourth phase of 2 two daily dosage units, each comprising a pharmaceutically acceptable placebo.

2. A multiphase oral contraception product comprising: a first phase of 2 daily oral dosage units, each comprising 3 mg of estradiol valerate, a second phase of 2 groups of daily oral dosage units, a first group comprising 5 daily oral dosage units, each of which comprises 2 mg of estradiol valerate and 2 mg of dienogest, and a second group comprising 17 daily oral dosage units, each of which comprises 2 mg of estradiol valerate and 3 mg of dienogest; a third phase of 2 daily oral dosage units, each comprising 1 mg of estradiol valerate, and a fourth phase of 2 daily oral dosage units, each comprising a pharmaceutically acceptable placebo.

3. A method of oral contraception comprising orally administering to a woman: one oral dosage unit comprising 3 mg of estradiol valerate daily for 2 days, then one oral dosage unit comprising 2 mg of estradiol valerate and 2 mg of dienogest daily for 5 days, then one oral dosage unit comprising 2 mg of estradiol valerate and 3 mg of dienogest daily for 17 days, then one oral dosage unit comprising 1 mg of estradiol valerate daily for 2 days, and then one oral dosage unit comprising a pharmaceutically acceptable placebo daily for 2 days.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Argus Health
Federal Trade Commission
Moodys
Julphar
Chubb
Healthtrust
QuintilesIMS
Cerilliant
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot